INT18654

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 5.73
Pain Relevance 2.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HRH2) signal transducer activity (HRH2)
HRH2 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 13 100.00 Very High Very High Very High
bradykinin 11 99.64 Very High Very High Very High
Potency 2 99.36 Very High Very High Very High
cINOD 1 99.36 Very High Very High Very High
peptic ulcer disease 5 99.16 Very High Very High Very High
Calcium channel 1 95.64 Very High Very High Very High
agonist 3 87.80 High High
peripheral neuropathy 1 81.76 Quite High
headache 1 80.84 Quite High
abdominal pain 1 80.44 Quite High
Disease Link Frequency Relevance Heat
Ulcers 12 99.16 Very High Very High Very High
INFLAMMATION 2 99.16 Very High Very High Very High
Disease 11 98.64 Very High Very High Very High
Adverse Drug Reaction 3 98.30 Very High Very High Very High
Gastroesophageal Reflux Disease 267 97.84 Very High Very High Very High
Congenital Anomalies 2 83.68 Quite High
Exanthema 1 82.16 Quite High
Peripheral Neuropathy 1 81.76 Quite High
Headache 1 80.84 Quite High
Cancer 1 80.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
Gene_expression (antagonists) of H2-receptor associated with peptic ulcer disease, antagonist and disease
1) Confidence 0.67 Published 1982 Journal Wien Med Wochenschr Section Title Doc Link 6126962 Disease Relevance 0.37 Pain Relevance 0.28
The agent offers little advantage over H2-receptor antagonists for the majority of patients with peptic ulcer.
Gene_expression (over) of H2-receptor associated with antagonist and ulcers
2) Confidence 0.47 Published 1990 Journal J. Clin. Gastroenterol. Section Abstract Doc Link 1978840 Disease Relevance 1.02 Pain Relevance 0.48
The pharmacology, pharmacokinetics, clinical efficacy, adverse reactions, drug interactions, and dosage of ranitidine are reviewed; specific comparisons are made of this new H2-receptor antagonist with the older agent, cimetidine.
Gene_expression (made) of H2-receptor associated with adverse drug reaction and antagonist
3) Confidence 0.36 Published 1982 Journal Clin Pharm Section Abstract Doc Link 6309467 Disease Relevance 0.10 Pain Relevance 0.09
Clinically significant drug interactions include (but are not limited to) antacids, proton pump inhibitors, histamine type 2 receptor antagonists, tenofovir, diltiazem, irinotecan, simvastatin, lovastatin, St.
Gene_expression (antagonists) of histamine type 2 receptor associated with antagonist
4) Confidence 0.21 Published 2004 Journal Pharmacotherapy Section Abstract Doc Link 15585441 Disease Relevance 1.01 Pain Relevance 0.29
Therapeutic substitutions are only permitted in a limited number of drug classes: histamine 2 receptor blockers, non-steroidal anti-inflammatory drugs, nitrates, angiotensin converting enzyme inhibitors, dihydropyridine calcium channel blockers and proton pump inhibitors.
Gene_expression (blockers) of histamine 2 receptor associated with inflammation, calcium channel and cinod
5) Confidence 0.16 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2994856 Disease Relevance 0.41 Pain Relevance 0.15
Another study suggested that the addition of a nocturnal H2RA (histamine-2 receptor antagonist) or PPI after taking a morning dose of PPI decreased nocturnal acid breakthrough with improvement of daytime functioning.50 Unfortunately, other data suggested tachyphylaxis with H2RAs in nocturnal acid breakthrough.51
Gene_expression (antagonist) of histamine-2 receptor associated with antagonist and gastroesophageal reflux disease
6) Confidence 0.09 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2879818 Disease Relevance 0.87 Pain Relevance 0.05
Another study suggested that the addition of a nocturnal H2RA (histamine-2 receptor antagonist) or PPI after taking a morning dose of PPI decreased nocturnal acid breakthrough with improvement of daytime functioning.50 Unfortunately, other data suggested tachyphylaxis with H2RAs in nocturnal acid breakthrough.51
Gene_expression (addition) of histamine-2 receptor associated with antagonist and gastroesophageal reflux disease
7) Confidence 0.09 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2879818 Disease Relevance 0.83 Pain Relevance 0.05
Another study suggested that the addition of a nocturnal H2RA (histamine-2 receptor antagonist) or PPI after taking a morning dose of PPI decreased nocturnal acid breakthrough with improvement of daytime functioning.50 Unfortunately, other data suggested tachyphylaxis with H2RAs in nocturnal acid breakthrough.51
Gene_expression (nocturnal) of histamine-2 receptor associated with antagonist and gastroesophageal reflux disease
8) Confidence 0.09 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2879818 Disease Relevance 0.82 Pain Relevance 0.05
Two compounds, [Hyp(3), Thi(5), Cha(8)]-BK and [Hyp(3), Thi(5), (N)Chg(7), Thi(8)]-BK, exhibited equivalent (or even greater) in vitro affinities and potencies to BK at the naturally expressed and recombinant hB2R.
Gene_expression (expressed) of hB2R associated with bradykinin
9) Confidence 0.00 Published 2009 Journal Peptides Section Abstract Doc Link 19111586 Disease Relevance 0.30 Pain Relevance 0.75

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox